

BPI INVEST GLOBAL HEALTH CARE FEEDER FUND

KEY INFORMATION AND INVESTMENT DISCLOSURE STATEMENT

As of December 31, 2021

Other Fees: 0.00%

FUND FACTS

Classification: Global Equity Feeder Fund

Launch Date: February 1, 2021

USD 1,000.00 **Minimum Investment:** Additional Investment: USD 500.00

Minimum Holding Period: None NAVPU: USD 99.14

Total Fund NAV (Mn): USD 7.27

Dealing Day: Daily up to 2:30 PM **Redemption Settlement:** T+5 End-of-Day

Early Redemption Charge: None

FEES

Trustee Fees: 1.00%

BPI Asset Management

As a percentage of average daily NAV for the quarter valued at USD 6.72 Million

Custodianship Fee: 0.00%

None

External Audit Fee: 0.00%

Isla Lipana

None

To be determined upon receipt

of billing

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve for its Participants long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Invest Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to limited participants in the market, low trading volumes, market disruptions, among others.

Country Risk:

Investors are exposed to the risk of loss arising from negative developments in the political, economic and social conditions of the focus countries of the underlying securities of the target fund, which may adversely affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**

For more information, you may contact us at (632) 8580-AMTC (2682), email us at bpi_asset_management@bpi.com.ph or visit our website, www.bpiassetmanagement.com.

FUND PERFORMANCE AND STATISTICS AS OF DECEMBER 31, 2021

(Purely for refe	rence purp	oses an	d is not a	guarante	e of futur	e results)
NAVPU GRAP	Н					
120 — F	und —	-Benchm	ark*	1	M	~
110		~	~			
100	~~~~	~~	····	m	~~~	~~
90 Feb-21 Mar-21 A	pr-21 May-21 J	lun-21 Jul-2	1 Jul-21 Aug	_J -21 Sep-21 (Oct-21 Nov-2	 1 Dec-21
*MSCI World He	ealth Care In	dex				
CUMULATIVE	PERFOR	MANCE	(%) ¹			
	1 mo	3 mos	6 mos	1YR	3YRS	S.I. ²
Fund	3.62	1.29	-2.42	-	-	-0.86
Benchmark	5.65	7.90	8.99	-	-	18.13
ANNUALIZED	PERFOR	MANCE	(%) ¹			
	1YR	2YRS	3YRS	4YRS	5YR	S.I. ²
Fund	-	-	-	-	-	-
Benchmark	-	-	-	-	-	-
CALENDAR Y	EAR PER	FORMA	NCE (%)	1		
	YTD					
Fund	-0.86					
Benchmark	18.13					
PORTFOLIO COMPOSITION						
Allocation					% of F	und
Target Fund					98.89	1

NAVPu over the past 12 months **Highest** 104.45 Lowest 93.05 **STATISTICS** Volatility, since inception (%) 3 12.85 Sharpe Ratio 4 -0.07 Information Ratio 5 -2.52 ¹ Returns are net of fees. ² Since Inception ³ Measures the degree to which the Fund fluctuates vis-àvis its average return over a period of time ⁴ Used to characterize how well the return of a Fund compensates the investor for the level of risk taken. The higher the number, the better. ⁵ Measures reward-to-risk efficiency of the portfolio relative to the benchmark. The higher the number, the est through

CALENDAR YEAR PERFORMANCE (%) 1		higher the reward per unit of risk.		
	*Declaration of Trust is av	ailable upon reque		
	your branch of account.			
% of Fund				
98.89	TOP TEN HOLDINGS			
2.84	Name	% of 7		
-1.73	UnitedHealth Group			
% of Target Fund				
75.26				
6.54				
5.40	AstraZeneca Plc.			
12.80	Boston Scientific			
% of Target Fund	Danaher Corp.			
17.42	Stryker Corp.			
17.13				
16.55				
15.57				
33.33	Zoeus mo.			
	98.89 2.84 -1.73 % of Target Fund 75.26 6.54 5.40 12.80 % of Target Fund 17.42 17.13 16.55 15.57	*Declaration of Trust is av your branch of account. *TOP TEN HOLDINGS *Name 1.73 *Name UnitedHealth Group Pfizer Inc. Eli Lily & Co. AstraZeneca Plc. Boston Scientific Danaher Corp. Stryker Corp. Bristol Myers Squibb Humana Inc. Zoetis Inc.		

RELATED PARTY TRANSACTIONS*	

The Fund has no transactions and outstanding investments with entities related to BPI Asset Management and Trust Corporation (RPLAMTC)

US Dollar

\cap TU	ЕВ		\mathbf{n}	\mathbf{E}^{A}	\sim T $^{\circ}$	-
OTH	EK	ΙСО	NU	ГΑ	CIS	•

Fund Currency:

(DPTAINTO).	
* Related party in accordance with BPI AMTC's internal policy.	

Fund structure:

UCITS (IRL)

Target Fund 6.90 4.77 4.76 3.57 3.55 2.65 2.43 2.13 1.98 1.98

Benchmark*: MSCI World Health Care Index Wellington Global Health Care Equity

Custodian:

Inception Date:

October 31, 2003 State Street Custodial Services

Name of Target Fund: Fund

(Ireland) Limited

Regulator: Central Bank of Ireland

Total Expense Ratio: 1.32%

Fund Manager: Wellington Management Company LLP

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

OUTLOOK AND STRATEGY

Market Review. Global equity markets started December under pressure due to escalating concerns over rising Omicron variant cases globally, the Federal Reserve's hawkish pivot and the rejection of Biden's USD \$2 Trillion economic agenda. Markets continued to be volatile for the whole month but finished the year on a positive note as sentiment improved driven by strong holiday sales and research reports that Omicron may be milder than expected.

In an effort to combat inflation, the Federal Reserve kept rates steady but doubled the pace of tapering their asset purchases with plans to end the bond-buying program by early 2022 instead of mid-year. Officials also forecasted a faster pace of rate hikes with the dot plot reflecting a median forecast of three rate hikes in 2022, another three in 2023 and two in 2024. The US central bank's hawkish pivot comes in contrast to the policy direction of China as its central bank cuts its reserve requirement ratio by 0.5% to support the country's stalling growth. The country's top officials also pledged to stabilize the economy in 2022 by increasing fiscal spending.

In commodity markets, oil prices remained volatile as the deepening energy shortage in Europe provided support while headwinds persisted in the form of continued weaker demand from the resurgence of the Omicron variant and expected slower economic growth.

Fund Performance: The fund returned 3.62% in December, lagging the benchmark by 204 basis points. Security selection detracted from performance.

Fund Strategy. COVID-19 disruptions will likely continue for many months, but we are encouraged by strong fundamentals across the healthcare industry, supported by hopes the Omicron wave could peak soon, leading the way to a more normalized investment backdrop. As we enter 2022, attractive valuations and breakthrough innovations in the biopharma industry are compelling and are creating a rich opportunity set for investors. Outside of biopharma, certain medical technology companies are seeing strong fundamentals as they help enable robust drug development and manufacturing in diverse therapeutic categories. COVID-19 testing, development of more convenient routine medical tests and expansion into new attractive categories, such as early cancer screening, should provide support for the diagnostics industry. Within procedure-oriented subsectors, medical devices are expected to experience increase in demand as patients resume elective procedures. These tailwinds across the various healthcare subsectors, coupled with strong valuation support leaves us with a positive outlook in 2022. The fund will continue to favor companies that develop innovative products designed to address important unmet medical needs. Over the long term, the tailwinds of innovation, an aging population and the globalization of demand cutting-edge Western-style medicines should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Asset Management and Trust Corporation (BPI AMTC) is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpi_asset_management@bpi.com.ph or call us at (02) 8580-AMTC (2682).

Regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph, BSP Webchat https://www.bsp.gov.ph

SMS: 021582277 & BSP CAMS Facebook https://www.facebook.com/BangkoSentralngPilipinas